← back to search

Atish D. Choudhury

Harvard University · US
Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics, Radiopharmaceutical Chemistry and Applications, and Cancer Immunotherapy and Biomarkers.
h-index
29
citations
5,866
works
347
NIH funding
primary concept
Medicine
email

Recent publications

High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Cancer Discovery 2025cited by 14position: middledoi
Data from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
2023cited by 0position: firstdoi
Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth
Nature Biomedical Engineering 2022cited by 79position: middledoi
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Cancer Discovery 2022cited by 66position: middledoi
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Clinical Cancer Research 2022cited by 40position: firstdoi
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Clinical Cancer Research 2022cited by 26position: middledoi
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer
Nature Cancer 2021cited by 240position: middledoi
Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer
The Journal of Urology 2021cited by 74position: middledoi
PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
Journal of Clinical Oncology 2021cited by 24position: middledoi
A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801).
Journal of Clinical Oncology 2021cited by 9position: middledoi
Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Clinical Cancer Research 2020cited by 192position: middledoi
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies
Cancer 2020cited by 111position: middledoi
Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing
Cell 2018cited by 378position: middledoi
Tumor fraction in cell-free DNA as a biomarker in prostate cancer
JCI Insight 2018cited by 145position: firstdoi
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Nature Communications 2017cited by 1,080position: middledoi
Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer
Cancer Research 2016cited by 0position: middledoi
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer
Nature Biotechnology 2014cited by 534position: middledoi
Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits
Integrative Biology 2014cited by 54position: middledoi
The Role of Genetic Markers in the Management of Prostate Cancer
European Urology 2012cited by 105position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

J. Christopher Love · Massachusetts Institute of Technology3 papers (2014–2022)Viktor A. Adalsteinsson · Broad Institute3 papers (2014–2022)Mary‐Ellen Taplin · Dana-Farber Cancer Institute3 papers (2014–2021)Toni K. Choueiri · Harvard University3 papers (2020–2021)Rana R. McKay · The Barbara Ann Karmanos Cancer Institute3 papers (2020–2021)Sarah C. Reed · Vanderbilt University2 papers (2018–2022)Ronald C. Chen · University of North Carolina at Chapel Hill2 papers (2021–2021) · 2 papers (2018–2022)Justin Rhoades · Broad Institute2 papers (2018–2022)Heather A. Parsons · Fred Hutch Cancer Center2 papers (2018–2022)Mark M. Pomerantz · Harvard University2 papers (2012–2021)Michael J. Morris · The University of Texas at Austin2 papers (2021–2021)Tyler Zemla · Mayo Clinic2 papers (2021–2021)David J. Einstein · Harvard University2 papers (2021–2022)Kerry L. Kilbridge · Harvard University2 papers (2020–2021) · 2 papers (2020–2021)Daniel G. Stover · Ohio University2 papers (2018–2022)Guru Sonpavde · AdventHealth Orlando2 papers (2020–2022)William C. Hahn · University of California System2 papers (2014–2018)Wanling Xie · Wuhan University2 papers (2020–2021)